drugset / Trial / NCT05022732

Polyglucosamine L112 in Overweight and Obese Subjects

NCT05022732 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This research proposes as its main purpose to evaluate the effectiveness of the intake of Polyglucosamine at a dose of 3 g / day on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 kg / m2). and with weight\> 75 kg

Timeline

Start
2020-05-05
Primary completion
2020-08-05
Completion
2021-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Polyglucosamine L112 Unknown 3 g —

Indications